Cover Image

Real-world evidence of the efficacy and tolerability of trabectedin in patients with advanced soft-tissue sarcoma

The efficacy and tolerability of trabectedin in patients with soft tissue sarcoma (STS) have been confirmed by various clinical studies involving lipo- and leiomyosarcomas as well as many other subtypes including translocation-related sarcomas. These data have been obtained from randomized phase II...

Full description

Saved in:
Bibliographic Details
Main Authors: Sande González, Luis Miguel de (Author) , Martin-Broto, Javier (Author) , Kasper, Bernd (Author) , Blay, Jean-Yves (Author) , Le Cesne, Axel (Author)
Format: Article (Journal)
Language:English
Published: 2020
In: Expert review of anticancer therapy
Year: 2020, Volume: 20, Issue: 11, Pages: 957-963
ISSN:1744-8328
DOI:10.1080/14737140.2020.1822744
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1080/14737140.2020.1822744
Verlag, lizenzpflichtig, Volltext: https://www.tandfonline.com/doi/full/10.1080/14737140.2020.1822744
Get full text
Author Notes:Luis Miguel de Sande González, Javier Martin-Broto, Bernd Kasper, Jean-Yves Blay & Axel Le Cesne
Description
Summary:The efficacy and tolerability of trabectedin in patients with soft tissue sarcoma (STS) have been confirmed by various clinical studies involving lipo- and leiomyosarcomas as well as many other subtypes including translocation-related sarcomas. These data have been obtained from randomized phase II and III clinical trials. Studies in real-world clinical practice are necessary to bridge the efficacy-effectiveness gap and complete the body of evidence. Furthermore, reinforcing clinical experience with data from routine clinical practice allows drug management to be optimized and clinical benefits to be maximized. The present review provides the most significant data on the efficacy of trabectedin in real-world studies, and the interpretation of real-world experience with trabectedin, in patients with advanced STS. Trabectedin has demonstrated durable disease control and an adequate safety profile, indicating it to be a suitable long-term treatment drug associated with a good quality of life. Personalized strategies and individualized objectives are the way forward in the management of STS.
Item Description:Gesehen am 02.09.2025
Physical Description:Online Resource
ISSN:1744-8328
DOI:10.1080/14737140.2020.1822744

Similar Items